文献速递糖尿病

基于生物标志物的筛查路径用于辅助诊断青年起病单基因糖尿病的群体评估

Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.
PubMed 文献 · Diabetes Care · 2017-01-01

研究在英国两个地区对≤30岁诊断且目前<50岁的患者实施三阶段生物标志物筛查路径:尿C肽/肌酐比值(UCPCR)≥0.2 nmol/mmol者检测GAD和IA2自身抗体,双阴性者进行35种单基因糖尿病亚型的分子遗传学检测。共1407例参与,新诊断17例单基因糖尿病,阳性预测值20%,阴性预测值99.9%,最低患病率3.6%(51/1407,95%CI 2.7-4.7%)。作者认为该路径有效、廉价且易于实施。

要点

  • UCPCR≥0.2 nmol/mmol的386/1365例(28%)中,216/386例(56%)GAD和IA2双阴性并接受分子遗传学检测。
  • 新诊断17例单基因糖尿病(8例常见MODY经Sanger测序,9例罕见病因经二代测序),加上已知34例,估计患病率3.6%(51/1407,95%CI 2.7-4.7%)。
  • 路径阳性预测值20%,阴性预测值99.9%。

核心结论

  • 作者认为,针对单基因糖尿病的生物标志物筛查路径是系统筛查所有青年起病患者的一种有效、廉价且易于实施的方法。
  • ≤30岁诊断的患者中单基因糖尿病最低患病率为3.6%。

研究设计与样本

  • 研究纳入在英国两个单基因糖尿病检出率已较高的地区、诊断年龄≤30岁且目前<50岁的患者。
  • 共1407例患者参与,其中1365例无已知遗传病因,34例已知单基因糖尿病,8例囊性纤维化相关糖尿病。
  • 筛查路径分三阶段:先测尿C肽/肌酐比值(UCPCR);UCPCR≥0.2 nmol/mmol者测GAD和IA2胰岛自身抗体;双阴性者进行35种单基因糖尿病亚型的分子遗传学诊断检测。

主要发现

  • 1365例无已知遗传病因患者中386例(28%)UCPCR≥0.2 nmol/mmol。
  • 386例中216例(56%)GAD和IA2双阴性并接受分子遗传学检测。
  • 新诊断17例单基因糖尿病(8例常见青少年的成人起病型糖尿病[MODY]经Sanger测序,9例罕见病因经二代测序),加上已知34例,估计患病率3.6%(51/1407,95%CI 2.7-4.7%)。
  • 路径阳性预测值为20%,提示约1/5的检出率;阴性预测值为99.9%。

关键数值与推荐

  • UCPCR阈值≥0.2 nmol/mmol作为进入自身抗体检测的阶段标准。
  • GAD和IA2双阴性作为进入分子遗传学检测的标准。
  • 分子遗传学检测覆盖35种单基因糖尿病亚型。

临床怎么用

  • 作者认为该生物标志物筛查路径可用于系统筛查所有青年起病患者,以筛选适合昂贵诊断性基因检测的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Monogenic diabetes, a young-onset form of diabetes, is often misdiagnosed as type 1 diabetes, resulting in unnecessary treatment with insulin. A screening approach for monogenic diabetes is needed to accurately select suitable patients for expensive diagnostic genetic testing. We used C-peptide and islet autoantibodies, highly sensitive and specific biomarkers for discriminating type 1 from non-type 1 diabetes, in a biomarker screening pathway for monogenic diabetes. RESEARCH DESIGN AND METHODS: We studied patients diagnosed at age 30 years or younger, currently younger than 50 years, in two U.K. regions with existing high detection of monogenic diabetes. The biomarker screening pathway comprised three stages: 1) assessment of endogenous insulin secretion using urinary C-peptide/creatinine ratio (UCPCR); 2) if UCPCR was ≥0.2 nmol/mmol, measurement of GAD and IA2 islet autoantibodies; and 3) if negative for both autoantibodies, molecular genetic diagnostic testing for 35 monogenic diabetes subtypes. RESULTS: A total of 1,407 patients participated (1,365 with no known genetic cause, 34 with monogenic diabetes, and 8 with cystic fibrosis-related diabetes). A total of 386 out of 1,365 (28%) patients had a UCPCR ≥0.2 nmol/mmol, and 216 out of 386 (56%) were negative for GAD and IA2 and underwent molecular genetic testing. Seventeen new cases of monogenic diabetes were diagnosed (8 common Maturity Onset Diabetes of the Young [Sanger sequencing] and 9 rarer causes [next-generation sequencing]) in addition to the 34 known cases (estimated prevalence of 3.6% [51/1,407] [95% CI 2.7-4.7%]). The positive predictive value was 20%, suggesting a 1-in-5 detection rate for the pathway. The negative predictive value was 99.9%. CONCLUSIONS: The biomarker screening pathway for monogenic diabetes is an effective, cheap, and easily implemented approach to systematically screening all young-onset patients. The minimum prevalence of monogenic diabetes is 3.6% of patients diagnosed at age 30 years or younger.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Shields BM, Shepherd M, Hudson M, et al. Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. Diabetes Care. 2017. PMID: 28701371. doi:10.2337/dc17-0224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。